PS
Portfolio Strategies, Inc.
13F filer · CIK 0001753271Reported Aug 10, 2026
Net buyer this quarter
13F portfolio value$1.02BU.S. long equity reported on 13F
Positions448 new · 5 closed
Net flow last quarter+$24.2MBuys minus sells
Top 10 positions weight23.9%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 10, 202644 positions | |||||
| $115M | 11.29% | Not reported | +7.5% | Q4 2019 | |
| $67.6M | 6.63% | Not reported | -0.8% | Q2 2018 | |
| $49.1M | 4.81% | Not reported | New | Q2 2026 | |
| $4.09M | 0.40% | 0.00% | -0.2% | Q4 2017 | |
| $2.17M | 0.21% | Not reported | Not reported | Q4 2017 | |
| $1.87M | 0.18% | 0.00% | -0.5% | Q4 2017 | |
| $1.39M | 0.14% | 0.00% | -0.9% | Q4 2017 | |
| $1M | 0.10% | Not reported | Not reported | Q4 2024 | |
| $874K | 0.09% | 0.00% | +0.7% | Q4 2017 | |
| $698K | 0.07% | 0.00% | Not reported | Q4 2017 | |
| $661K | 0.06% | 0.00% | Not reported | Q1 2019 | |
| $643K | 0.06% | Not reported | +0.8% | Q4 2017 | |
| $569K | 0.06% | 0.00% | Not reported | Q4 2017 | |
| $538K | 0.05% | 0.00% | Not reported | Q1 2026 | |
| $474K | 0.05% | 0.00% | Not reported | Q4 2017 | |
| $450K | 0.04% | 0.00% | Not reported | Q4 2017 | |
| $440K | 0.04% | 0.03% | Not reported | Q3 2025 | |
| $427K | 0.04% | 0.00% | -4.1% | Q4 2017 | |
| $405K | 0.04% | 0.00% | Not reported | Q1 2026 | |
| $404K | 0.04% | 0.00% | Not reported | Q1 2026 | |
| $377K | 0.04% | 0.01% | Not reported | Q4 2017 | |
| $374K | 0.04% | 0.00% | Not reported | Q4 2017 | |
| $362K | 0.04% | 0.00% | Not reported | Q4 2024 | |
| $357K | 0.04% | 0.00% | Not reported | Q4 2017 | |
| $353K | 0.03% | 0.00% | New | Q2 2026 | |
| $346K | 0.03% | Not reported | -3.1% | Q4 2017 | |
| $338K | 0.03% | 0.00% | Not reported | Q4 2017 | |
| $320K | 0.03% | 0.00% | -5.2% | Q2 2018 | |
| $318K | 0.03% | 0.01% | Not reported | Q4 2020 | |
| $311K | 0.03% | 0.00% | +1.0% | Q2 2025 | |
| $301K | 0.03% | 0.00% | Not reported | Q4 2017 | |
| $268K | 0.03% | 0.00% | Not reported | Q1 2026 | |
| $261K | 0.03% | 0.00% | +0.2% | Q4 2017 | |
| $258K | 0.03% | 0.00% | Not reported | Q4 2017 | |
| $256K | 0.03% | Not reported | -3.2% | Q3 2025 | |
| $242K | 0.02% | 0.00% | +0.6% | Q4 2017 | |
| $239K | 0.02% | Not reported | New | Q2 2026 | |
| $235K | 0.02% | 0.00% | Not reported | Q1 2026 | |
| $229K | 0.02% | 0.00% | -13.7% | Q1 2026 | |
| $213K | 0.02% | 0.00% | Not reported | Q4 2017 | |
| $212K | 0.02% | 0.00% | Not reported | Q4 2017 | |
| $212K | 0.02% | 0.00% | New | Q2 2026 | |
| $203K | 0.02% | 0.00% | Not reported | Q4 2017 | |
| BTBTAIBioXcel Therapeutics, Inc. | $23.7K | 0.00% | 0.05% | +38.2% | Q4 2025 |
| Q1 2026Reported May 5, 202641 positions | |||||
| $62.6M | 7.72% | Not reported | -21.2% | Q4 2019 | |
| $53.4M | 6.59% | Not reported | -1.5% | Q2 2018 | |
| $19.7M | 2.43% | 0.25% | +1840.2% | Q4 2025 | |
| $3.59M | 0.44% | 0.00% | +15.4% | Q4 2017 | |
| $1.86M | 0.23% | 0.00% | +29.4% | Q4 2017 | |
| $1.76M | 0.22% | Not reported | +13.8% | Q4 2017 | |
| $1.22M | 0.15% | 0.00% | +18.6% | Q4 2017 | |
| $1.16M | 0.14% | Not reported | +2.9% | Q4 2024 | |
| $1.11M | 0.14% | 0.00% | +20.4% | Q4 2017 | |
| $665K | 0.08% | 0.00% | +16.5% | Q4 2017 | |
| $631K | 0.08% | 0.00% | Not reported | Q1 2019 | |
| $611K | 0.08% | Not reported | Not reported | Q4 2017 | |
| $561K | 0.07% | 0.00% | Not reported | Q4 2017 | |
| $553K | 0.07% | 0.00% | -3.4% | Q4 2017 | |
| $513K | 0.06% | 0.03% | Not reported | Q3 2025 | |
| $424K | 0.05% | 0.00% | Not reported | Q4 2017 | |
| $405K | 0.05% | 0.00% | Not reported | Q4 2017 | |
| $370K | 0.05% | 0.00% | Not reported | Q4 2017 | |
| $362K | 0.04% | 0.00% | Not reported | Q2 2018 | |
| $340K | 0.04% | 0.00% | New | Q1 2026 | |
| $325K | 0.04% | 0.01% | Not reported | Q4 2017 | |
| $319K | 0.04% | 0.01% | Not reported | Q4 2020 | |
| $318K | 0.04% | 0.00% | New | Q1 2026 | |
| $311K | 0.04% | Not reported | +4.4% | Q4 2017 | |
| $298K | 0.04% | 0.00% | Not reported | Q4 2017 | |
| $297K | 0.04% | 0.00% | -2.6% | Q4 2024 | |
| $286K | 0.04% | 0.00% | Not reported | Q4 2017 | |
| $280K | 0.03% | 0.00% | New | Q1 2026 | |
| $273K | 0.03% | 0.00% | -0.5% | Q4 2017 | |
| $269K | 0.03% | 0.00% | -2.6% | Q2 2025 | |
| $261K | 0.03% | Not reported | -24.0% | Q3 2025 | |
| $254K | 0.03% | 0.00% | Not reported | Q4 2017 | |
| $241K | 0.03% | 0.00% | Not reported | Q4 2017 | |
| $238K | 0.03% | 0.00% | New | Q1 2026 | |
| $213K | 0.03% | 0.00% | New | Q1 2026 | |
| $211K | 0.03% | 0.00% | -1.2% | Q4 2017 | |
| $209K | 0.03% | 0.00% | New | Q1 2026 | |
| $205K | 0.03% | 0.00% | New | Q1 2026 | |
| $203K | 0.03% | 0.00% | New | Q1 2026 | |
| BTBTAIBioXcel Therapeutics, Inc. | $16.3K | 0.00% | 0.05% | Not reported | Q4 2025 |
| $3.43K | 0.00% | 0.07% | Not reported | Q1 2025 | |
| Q4 2025Reported Jan 27, 202629 positions | |||||
| $74.6M | 8.64% | Not reported | -3.8% | Q4 2019 | |
| $57.7M | 6.68% | Not reported | -1.7% | Q2 2018 | |
| $3.33M | 0.39% | 0.00% | -1.8% | Q4 2017 | |
| $1.88M | 0.22% | 0.00% | -1.0% | Q4 2017 | |
| $1.7M | 0.20% | Not reported | -1.6% | Q4 2017 | |
| $1.14M | 0.13% | 0.00% | -1.9% | Q4 2017 | |
| $1.05M | 0.12% | Not reported | -0.4% | Q4 2024 | |
| $980K | 0.11% | 0.00% | Not reported | Q4 2017 | |
| $927K | 0.11% | 0.01% | New | Q4 2025 | |
| $869K | 0.10% | 0.00% | -2.8% | Q4 2017 | |
| $641K | 0.07% | Not reported | Not reported | Q4 2017 | |
| $611K | 0.07% | 0.00% | -1.2% | Q4 2017 | |
| $543K | 0.06% | 0.00% | Not reported | Q1 2019 | |
| $525K | 0.06% | 0.00% | -0.9% | Q4 2017 | |
| $473K | 0.05% | 0.03% | -1.7% | Q3 2025 | |
| $406K | 0.05% | 0.00% | +11.5% | Q4 2017 | |
| $373K | 0.04% | 0.00% | Not reported | Q2 2024 | |
| $371K | 0.04% | Not reported | -1.0% | Q3 2025 | |
| $348K | 0.04% | 0.00% | Not reported | Q4 2017 | |
| $341K | 0.04% | 0.00% | +0.5% | Q4 2024 | |
| $339K | 0.04% | 0.00% | -0.1% | Q4 2017 | |
| $317K | 0.04% | 0.01% | Not reported | Q4 2017 | |
| $312K | 0.04% | Not reported | +4.8% | Q4 2017 | |
| $295K | 0.03% | 0.00% | -1.7% | Q2 2025 | |
| $290K | 0.03% | 0.00% | Not reported | Q4 2017 | |
| $289K | 0.03% | 0.01% | Not reported | Q4 2020 | |
| $245K | 0.03% | 0.00% | Not reported | Q4 2017 | |
| BTBTAIBioXcel Therapeutics, Inc. | $19.5K | 0.00% | 0.05% | New | Q4 2025 |
| $16K | 0.00% | 0.22% | Not reported | Q1 2025 | |
| Q3 2025Reported Oct 29, 202529 positions | |||||
| $70.3M | 8.17% | Not reported | -3.2% | Q4 2019 | |
| $57.4M | 6.67% | Not reported | -1.1% | Q2 2018 | |
| $3.18M | 0.37% | 0.00% | -3.0% | Q4 2017 | |
| $2.03M | 0.24% | 0.00% | -3.3% | Q4 2017 | |
| $1.33M | 0.15% | Not reported | -0.8% | Q4 2017 | |
| $1.12M | 0.13% | 0.00% | Not reported | Q4 2017 | |
| $1.11M | 0.13% | 0.00% | -3.9% | Q4 2017 | |
| $903K | 0.10% | Not reported | +16.6% | Q4 2024 | |
| $641K | 0.07% | Not reported | Not reported | Q4 2017 | |
| $605K | 0.07% | 0.00% | -0.6% | Q1 2019 | |
| $588K | 0.07% | 0.00% | +84.2% | Q4 2017 | |
| $504K | 0.06% | Not reported | New | Q3 2025 | |
| $490K | 0.06% | 0.00% | Not reported | Q2 2024 | |
| $480K | 0.06% | 0.00% | Not reported | Q4 2017 | |
| $475K | 0.06% | 0.00% | +50.2% | Q4 2017 | |
| $431K | 0.05% | 0.03% | New | Q3 2025 | |
| $397K | 0.05% | 0.00% | Not reported | Q4 2017 | |
| $382K | 0.04% | Not reported | New | Q3 2025 | |
| $350K | 0.04% | 0.00% | -1.8% | Q4 2017 | |
| $341K | 0.04% | 0.00% | -21.9% | Q4 2017 | |
| $333K | 0.04% | Not reported | New | Q3 2025 | |
| $322K | 0.04% | 0.00% | Not reported | Q4 2024 | |
| $319K | 0.04% | 0.01% | Not reported | Q4 2017 | |
| $295K | 0.03% | 0.00% | +0.3% | Q2 2025 | |
| $291K | 0.03% | Not reported | +12.6% | Q4 2017 | |
| $289K | 0.03% | 0.00% | Not reported | Q4 2017 | |
| $283K | 0.03% | 0.01% | Not reported | Q4 2020 | |
| $205K | 0.02% | 0.00% | -1.8% | Q4 2017 | |
| $25.3K | 0.00% | 0.27% | Not reported | Q1 2025 | |
Premium opens every quarter this fund has filed